LT4 Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Liquidia Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.70 |
| 52 Week High | US$15.56 |
| 52 Week Low | US$6.75 |
| Beta | 0.22 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | 190.27% |
| Change since IPO | -26.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| LT4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.1% | 4.5% |
| 1Y | n/a | -12.1% | 13.4% |
Return vs Industry: Insufficient data to determine how LT4 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LT4 performed against the German Market.
Price Volatility
| LT4 volatility | |
|---|---|
| LT4 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LT4 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LT4's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 145 | Roger Jeffs | www.liquidia.com |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.
Liquidia Corporation Fundamentals Summary
| LT4 fundamental statistics | |
|---|---|
| Market cap | €756.44m |
| Earnings (TTM) | -€100.41m |
| Revenue (TTM) | €13.29m |
56.9x
P/S Ratio-7.5x
P/E RatioIs LT4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LT4 income statement (TTM) | |
|---|---|
| Revenue | US$14.84m |
| Cost of Revenue | US$4.52m |
| Gross Profit | US$10.32m |
| Other Expenses | US$122.43m |
| Earnings | -US$112.11m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.33 |
| Gross Margin | 69.52% |
| Net Profit Margin | -755.46% |
| Debt/Equity Ratio | 137.0% |
How did LT4 perform over the long term?
See historical performance and comparison